Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?

Future Oncol. 2017 Feb;13(5):381-383. doi: 10.2217/fon-2016-0462. Epub 2016 Nov 25.
No abstract available

Keywords: circulating tumor cells; immune checkpoint inhibitors; minimal residual disease.

Publication types

  • Editorial
  • Letter

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors
  • CTLA-4 Antigen / antagonists & inhibitors
  • Humans
  • Immunomodulation / drug effects*
  • Molecular Targeted Therapy*
  • Neoplasm, Residual / pathology*
  • Neoplasms / diagnosis*
  • Neoplasms / drug therapy*
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • B7-H1 Antigen
  • CTLA-4 Antigen
  • Programmed Cell Death 1 Receptor